Pharmaceutical firm Novo Nordisk is poised to surpass its trading forecasts, buoyed by surging demand for its new Wegovy weight loss pill. Shares in the Copenhagen-based company saw a significant uplift in early trading on Wednesday following the announcement. The launch of the Wegovy pill in January marked a direct challenge to rival Mounjaro, produced by Eli Lilly, in the competitive weight loss drug market. This success comes after the Danish firm experienced a downturn in sales and profits for its injection treatments, which were significantly impacted by the rapid rise of competitor weight loss pills. Novo Nordisk has hailed the Wegovy pill’s debut as the strongest for any obesity drug in the US market. Since its introduction, more than two million prescriptions have been issued, with weekly figures now surpassing 200,000. The Wegovy pill (Wegovy) Sales of the pill reach 2.26 billion Danish krone (£261 million) in the quarter to March 31, surpassing analyst predictions.…